Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RRZWJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN117337196A Compound93
|
|||||
| Synonyms |
30kmPEG (SCAPDL1xSCACD47)-2 (Val-Cit-PAB-DEA-Dxd)
Click to Show/Hide
|
|||||
| Organization |
Shenzhen Enduring Biotech Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1
|
|||||
| Structure |
|
|||||
| Antibody Name |
SCAPDL1xSCACD47
|
Antibody Info | ||||
| Antigen Name |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47)
|
Antigen Info | ||||
| Payload Name |
DX-8951 derivative (DXd)
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA-Dxd)
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line Calu6 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 0% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 7% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 8% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 18% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 18% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line Calu6 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 25% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 28% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 30% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 35% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 38% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 38% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line Calu6 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 45% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 60% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 75% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||